Testing Brain Tumor Treatments on Lab-Grown Tumor Models From Patients
Lab-grown models of glioblastoma from patients' tumors are tested with experimental treatments.
Plain-language title generated from the registry record
Registry title: Patient's Derived Organoids for Drug Screening in Glioblastoma
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06781372
- Record updated
- 13 March 2025
- Original description
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention. In fact, tumor removed from patients' brains will be sent to a dedicated laboratory to obtain an "avatar" of the tumor, named patient-derived organoid (PDO). A number of experimental antitumor approaches will be studied on PDOs. Results of these experiments will be correlated to the prognosis of patients.Read full original descriptionShow less
Development and Characterization of Patient's Derived Organoids as a Platform for the Screening of Novel Therapeutic Treatments for Glioblastoma Multiforme
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention. In fact, tumor removed from patients' brains will be sent to a dedicated laboratory to obtain an "avatar" of the tumor, named patient-derived organoid (PDO). A number of experimental antitumor approaches will be studied on PDOs. Results of these experiments will be correlated to the prognosis of patients.
Inclusion: adult patients undergoing resective neurosurgery for glioblastoma, IDH-wildtype.
Exclusion: Previous neoadjuvant chemotherapy or radiotherapy; Brain surgery for tumor disease other than GBM; Age <18 years; Needle biopsies; Inability to give informed consent.